MOUNTAIN VIEW, Calif., Sept. 8 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, plans to announce the results from the EQUIP and CONQUER Qnexa(TM) phase 3 obesity clinical trials on September 9th prior to market open. The announcement will be followed by a webcast and conference call at 8:00 a.m. Eastern time.
Conference Call Information
Domestic callers: 1-800-967-7185
International callers: 1-719-325-2352
Webcast information: http://ir.vivus.com. A webcast replay will be available on the VIVUS web site for 30 days.
VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa(TM), has recently completed phase 3 clinical trials for the treatment of obesity. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.
CONTACT: VIVUS, Inc. Investor Relations: The Trout Group Timothy E. Morris Brian Korb Chief Financial Officer 646-378-2923 650-934-5200 Media Relations: Pure Communications, Inc. Sheryl Seapy 949-608-0841
|SOURCE VIVUS, Inc.|
Copyright©2009 PR Newswire.
All rights reserved